Results 1 to 10 of about 144,374 (198)

Hereditary angioedema (HAE) in Belgium: results from a national survey. [PDF]

Front Allergy, 2023
BackgroundHereditary angioedema (HAE) is a rare heritable disorder that is characterized by recurrent, circumscribed, nonpitting, nonpruritic, often painful subepithelial swellings of sudden unpredictable onset that generally fade during 48–72 h. Epidemiological data of hereditary angioedema patients in Belgium is lacking.MethodsWe set up a nation-wide,
Van der Poorten MM, Schrijvers R, Hermans C, Bartiaux M, Haerynck F, Lapeere H, Moutschen M, Michel O, Sabato V, Ebo DG, Van Gasse AL.   +10 more
europepmc   +12 more sources

Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability. [PDF]

Ther Clin Risk Manag, 2023
Hereditary angioedema (HAE) is a condition characterized by episodes of cutaneous and submucosal edema. Angioedema of the extremities and abdominal attacks are the most common manifestations of the disease. It can also affect the upper airways with the potential of becoming life-threatening.
Diaz-Menindez M, Morgenstern-Kaplan D, Cuervo-Pardo L, Alvarez-Arango S, Gonzalez-Estrada A.   +4 more
europepmc   +6 more sources

A patient with hereditary angioedema (HAE) with normal C1-INH and SLE with pregnancy. [PDF]

J Allergy Clin Immunol Glob, 2023
The case of a 24-year-old female patient with hereditary angioedema, a normal C1 esterase inhibitor level, SLE, and pregnancy is reported.
Taha OS, Abi Melhem R, Taha Y, Meyer D, Assaad M.   +4 more
europepmc   +3 more sources

The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews. [PDF]

Orphanet J Rare Dis, 2022
AbstractBackgroundHereditary angioedema (HAE) is a genetic disorder characterized by re-occurring swelling episodes called “attacks,” usually in the limbs, face, airways, and intestinal tract. New prophylactic therapies have reduced the frequency of these attacks.
Jean-Baptiste M, Itzler R, Prusty S, Supina D, Martin ML.   +4 more
europepmc   +4 more sources

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries. [PDF]

Orphanet J Rare Dis, 2022
AbstractHereditary angioedema (HAE) is a rare autosomal dominant genetic disease characterized by repetitive subcutaneous or submucosal angioedema, activation of the kinin system, and increased vascular permeability. C1-inhibitor (C1-INH) deficiency, the main mechanism of HAE pathogenesis, occurs when abnormal activation of plasma kallikrein ...
Guo Y, Zhang H, Lai H, Wang H, Chong-Neto HJ, Valle SOR, Zhu R.   +6 more
europepmc   +4 more sources

Hereditary angioedema (HAE) in children and adolescents: New treatment options. [PDF]

Allergol Select
Modern management of hereditary angioedema (HAE) due to reduced C1 inhibitor (C1-INH) function or concentration (HAE-C1-INH) focuses on individualized therapeutic strategies to address the specific needs of children and adolescents as well as the severity of the disease.
Fasshauer M, Wedi B.
europepmc   +3 more sources

Hereditary angioedema (HAE): a cause for recurrent abdominal pain. [PDF]

BMJ Case Rep, 2016
A 44-year-old Hispanic woman presented to the emergency room with a 2-day history of sudden onset of severe cramping left lower quadrant abdominal pain associated with ∼20 episodes diarrhoea. Abdominal CT scan exhibited bowel wall oedema and acute extensive colitis.
Soni P, Kumar V, Alliu S, Shetty V.
europepmc   +4 more sources

Berotralstat Tolerability and Effectiveness in Hereditary Angioedema: Berolife Study Results. [PDF]

Clin Transl Allergy
ABSTRACT Background Berotralstat is a first‐line once‐daily oral prophylactic treatment for hereditary angioedema (HAE). Berolife was designed to evaluate the tolerability and effectiveness of berotralstat in real‐world conditions. Methods Berolife is an open‐label, multicenter, observational study conducted in France from September 2021 to January ...
Gobert D, Launay D, Boccon-Gibod I, Bourgoin-Heck M, Hoarau C, Ollivier Y, Maillard H, Pontille F, Ozanne N, Aubineau M, de Moreuil C, Gerber A, Pelletier F, Jeandel PY, Du-Thanh A, Dalmas MC, Taquet MC, Schmidt J, Servettaz A, Perier A, Cohen E, Carriat L, Lemaire N, Villedieu M, Crave JC, Fain O, Bouillet L.   +26 more
europepmc   +2 more sources

The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks. [PDF]

Allergy Asthma Clin Immunol
Abstract Background Hereditary angioedema (HAE) is characterized by debilitating attacks of tissue swelling in various locations. While guidelines recommend the importance of early on-demand treatment, recent data indicate that many patients delay or do not treat their attacks ...
Betschel SD, Caballero T, Jones DH, Longhurst HJ, Manning M, van Kooten S, Heckmann M, Danese S, Goga L, Burnette AF.   +9 more
europepmc   +6 more sources

Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study. [PDF]

Clin Transl Allergy
ABSTRACT Background Lanadelumab has been approved for hereditary angioedema (HAE) long‐term prophylaxis since 2018. The Phase 4, prospective ENABLE Study (NCT04130191) evaluated the long‐term effectiveness and safety of lanadelumab in clinical practice across Europe and the Middle East.
Zanichelli A, Wuillemin WA, Magerl M, Recke A, Cancian M, Aygören-Pürsün E, Bellfill RL, Kessel A, Kinaciyan T, Lochbaum R, Al-Ahmad M, Andresen I, Watt M, Khutoryansky N, Castaner DN, Martinez-Saguer I.   +15 more
europepmc   +2 more sources